The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer

BACKGROUND: Ovarian cancer has the highest mortality rate among gynecological malignancies and is associated with poor prognosis. Since the accurate assessment of the global burden along with the trend of cancers contributes to the development of policies, this study aimed to explain the incidence, mortality, and burden of ovarian cancer using the global burden of disease (GBD) 2019 study. METHODS: Epidemiological data have been collected from the study of the GBD 2019. Data were extracted globally for 204 countries and groups based on a socio‐demographic index (SDI), WHO regions, continents, World Bank regions, and 22 GBD regions. RESULTS: In 2019, a total of 294,422 new cases of ovarian cancer were reported. The highest age‐standardized incidence rate (ASIR) was reported in areas with higher SDI, World high‐income countries, continental Europe, and then America. In GBD regions, the highest age‐standardized incidence is in Central Europe. In 2019, a total of 198,412 deaths due to ovarian cancer were reported. The highest ASR death is related to countries with high SDI and the World Bank high‐income countries. In 2019, adjusted years of life with disabilities (DALYs) due to ovarian cancer were reported to be 5,359,737, of which 5,205,660 were related to lost years of life (YLLs), and 154,077 were related to years of life with disabilities (YLDs). CONCLUSIONS: In 2019, the highest age‐standardized incidence of ovarian cancer, ASR death, and DALYs ASR belong to the high SDI countries. Designing interventions based on risk factors as well as providing preventive approaches to reduce the risk of this cancer, improving the treatment of ovarian cancer, and using appropriate and invasive treatments are recommended.